Angiotensin-Converting Enzyme Inhibitors - Pharmacology
Research News and Information

Sunday, November 22, 2009

Long-term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study.

29 Sep 2009 OBJECTIVES: The aim of this study was to investigate the long-term effects of perindopril on left ventricular (LV) systolic and diastolic function in patients with stable coronary artery disease who had previously undergone coronary artery bypass ... Read more...

Role of renin-angiotensin system blockade in patients with diabetes mellitus.

13 Sep 2009 The investigators review the evidence of the potential role of renin-angiotensin system (RAS) blockers in delaying or preventing the onset and progression of diabetes mellitus (DM) and cardiovascular disease and the suggested mechanisms by which ... Read more...

Decreased renal perfusion rapidly increases plasma membrane Na-K-ATPase in rat cortex by an angiotensin II-dependent mechanism.

31 Aug 2009 To understand how rapid changes in blood pressure can regulate Na-K-ATPase in the kidney cortex, we tested the hypothesis that a short-term (5 min) decrease in renal perfusion pressure will increase the amount of Na-K-ATPase in the plasma membranes ... Read more...

Latest indexed articles for 'Angiotensin-Converting Enzyme Inhibitors - Pharmacology'

These are the very latest articles for this heading:

• Long-term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study. 29 Sep 2009
• Renal and retinal effects of enalapril and losartan in type 1 diabetes. 29 Sep 2009
• Role of renin-angiotensin system blockade in patients with diabetes mellitus. 13 Sep 2009
• Decreased renal perfusion rapidly increases plasma membrane Na-K-ATPase in rat cortex by an angiotensin II-dependent mechanism. 31 Aug 2009
• Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. 15 Aug 2009
• Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. 15 Aug 2009
• Moving beyond angiotensin II to also target aldosterone? 2 Aug 2009
• Diabetes mellitus is associated with increased ex vivo-platelet aggregation and decreased response to aspirin - antithrombotic potential of ACE-inhibitors and AT1-antagonists. 30 Jul 2009
• Goat whey fermentation by Kluyveromyces marxianus and Lactobacillus rhamnosus release tryptophan and tryptophan-lactokinin from a cryptic zone of alpha-lactalbumin. 30 Jul 2009
• Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. 30 Jul 2009
• Diabetes, insulin, and development of acute lung injury. 30 Jul 2009
• Circulating endothelial progenitor cells and age-related white matter changes. 21 Jul 2009
• Dual renin-angiotensin system blockade and kidney disease. 12 Jul 2009
• Diabetes complications and the renin-angiotensin system. 30 Jun 2009
• Renal and retinal effects of enalapril and losartan in type 1 diabetes. 30 Jun 2009
• Current pharmacological approach to restore endothelial dysfunction. 29 Jun 2009
• Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients. 29 Jun 2009
• Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension? 29 Jun 2009
• Cardiovascular protection: a breakthrough for high-risk patients? 29 Jun 2009
• Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Angiotensin-Converting Enzyme Inhibitors'

Definition: A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Registry Number: 0

Descriptor UI: D000806

Alternative terms: Angiotensin-Converting Enzyme Inhibitors; Angiotensin Converting Enzyme Inhibitors; Antagonists, Angiotensin-Converting Enzyme; Antagonists, Angiotensin Converting Enzyme; Angiotensin I-Converting Enzyme Inhibitors; Angiotensin I Converting Enzyme Inhibitors; Inhibitors, Angiotensin-Converting Enzyme; Enzyme Inhibitors, Angiotensin-Converting; Inhibitors, Angiotensin Converting Enzyme; ACE Inhibitors; Kininase II Antagonists; Inhibitors, Kininase II; Kininase II Inhibitors; Inhibitors, ACE; Angiotensin-Converting Enzyme Antagonists; Angiotensin Converting Enzyme Antagonists; Enzyme Antagonists, Angiotensin-Converting; Antagonists, Kininase II;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.389.745.085;

Online Note: use TEPROTIDE to search ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR 1991-93

History Note: 88; ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR was see TEPROTIDE 1991-93

Technical Notes: protease inhib & antihypertensives; DF: ACE INHIB